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BACKGROUND: Several studies have shown that testing for high-risk human papillomavirus (HPV) types results in an improved sensitivity
for CIN2þ , compared with cytology, although with a somewhat lower specificity.
METHODS:We obtained follow-up results, with at least one smear after participation in the HART study, which compared HPV testing
(HC-II) with cytology as a primary screening modality.
RESULTS: With a median follow-up of 6 years, 42 additional cases of CIN2þ were identified; women who were HPV positive at
baseline were more likely to develop CIN2þ than those who were HPV negative (hazard ratio (HR) 17.2; 95% confidence interval
(CI) (9.3–31.6)) and the risk increased with increasing viral load. Compared with HPV-negative women (relative light unit (RLU)
o1), the HR (95% CI) was 5.4 (1.6, 18.2) for 1–10 RLU and 25.5 (13.6, 47.9) for RLUX10. Positive cytology (borderline or worse
compared with negative) was also predictive of developing CIN2, although to a lesser extent (HR 8.7; 95% CI (4.5–17.1)). Only one
case of CIN3 and three cases of CIN2 were found in women who showed a positive cytology result but were HPV negative at
baseline.
CONCLUSION: After 5 years of follow-up, CIN2þ occurred in 0.23% of women who were HPV negative at baseline compared with
0.48% of women who showed a negative cytology result, indicating a much longer low-risk interval for CIN2þ after HPV testing.
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The introduction of cervical screening programmes based on
cytology has led to a substantial reduction in the incidence of
cervical cancer in countries in which it has been adequately
organised (Laara et al, 1987; Sasieni et al, 2003; Bray et al, 2005;
van der Aa et al, 2008). However, cytology is a subjective test with
comparatively low sensitivity (50–75%) to detect CIN2 or worse
(CIN2þ ) (Cuzick et al, 2006). Hence, regular screens at relatively
short intervals are required. High-risk types of the human
papillomavirus (HPV) are present in almost all cervical cancers
(Clifford et al, 2006), and it has been shown in several studies that
testing for these high-risk HPV types results in an improved
sensitivity for CIN2þ compared with cytology, although at a
somewhat lower specificity (especially in younger women) (Cuzick
et al, 2006; Leinonen et al, 2009). Recently published results have
reported that a negative HPV result is associated with a greater
long-term protection from CIN2þ compared with a normal
cytology result (Bulkmans et al, 2007; Cuzick et al, 2008; Dillner
et al, 2008).
In this study, we report results on the long-term follow-up of the
HART study (Cuzick et al, 2003) and examine long-term
protection after a negative HPV test result alone compared with
a negative cytology result, or a negative result on both tests.
MATERIALS AND METHODS
A total of 11 085 women, aged 30–60 years, were recruited from
161 family practices associated with five UK laboratories or referral
centres in Birmingham, Edinburgh, London, Manchester and
Mansfield. Women were recruited and attended an initial visit
between June 1998 and July 2001. Women were excluded if they
had had an abnormal smear within the last 3 years or had been
previously treated for CIN. At the initial baseline visit, two cervical
samples were taken; the first, for conventional cytology, was taken
with an extended-tip spatula, the second sample was taken using a
cone-shaped cervical sampler brush (Qiagen, Hilden, Germany),
which was placed into specimen transport medium for transportation
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to one of two laboratories. This second sample was tested for
high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68) using the Digene (now Qiagen) Hybrid Capture II kit (HC-II).
Patients were considered HPV positive if their result was above the
1 relative light unit (RLU) control value, in keeping with the
manufacturer’s instructions. Risk associated with increasing RLU
levels was also investigated to determine the impact of viral load.
Women with mild dyskaryosis or worse or with two to three
inadequate cytology results were referred to colposcopy. Women
with a borderline smear or an HPV-positive result (or both) were
randomised into two equal groups to receive immediate colpo-
scopy or a further cytology and HPV test in 6–12 months. Those
with both a negative cytology and a negative HPV test result were
considered disease free and continued routine screening. However,
460 of these women were randomly selected for colposcopy to
ascertain disease rates in this subgroup of women.
Full details of testing and management of women at baseline are
given in the baseline paper (Cuzick et al, 2003).
All women were followed up to determine results of subsequent
routine cytology screening. Any ensuing colposcopy and biopsy
results were also obtained. Follow-up commenced at the date
of the baseline HART test and continued until the last recorded
smear, which varied between December 2006 and March 2008
according to centre. Any discrepancies between baseline and
follow-up data were checked at the relevant cytology/histology
laboratories where possible. If we were unable to verify the result
at the laboratory, then the most recent results from the centre
were used.
Follow-up cytology was obtained using either an internally
developed computer system (Mansfield, Manchester, Edinburgh),
the national computerised call/recall NHAIS system (usually
referred to as Open Exeter) (London) or a combination of both
systems (Birmingham, with discrepancies being resolved by a
review of laboratory records). Follow-up colposcopy and histology
results were obtained for each centre using their internal computer
systems.
Criteria for referral to colposcopy varied between different sites:
Birmingham – one mild dyskaryosis or worse; three borderline or
inadequate smears. After biopsy, all women with high-grade
disease were treated, and some cases of low-grade disease as well.
Edinburgh – one moderate dyskaryosis or worse, or glandular
abnormality; two mild dyskaryosis; three borderline; three
inadequate smears. An option of treatment or conservative
management was offered to patients with biopsy-confirmed CIN1
and all CIN2 or worse cases were offered treatment. London – one
mild dyskaryosis or worse; three borderline or inadequate smears.
An option of treatment or conservative management was offered to
patients with biopsy-confirmed CIN1 and all CIN2 cases or worse
were offered treatment. Manchester – one mild dyskaryosis or
worse; three borderline or inadequate smears. After biopsy, all
cases of high-grade and some cases of low-grade disease were
treated. Mansfield – two mild dyskaryosis or worse; two borderline
or three inadequate smears. After biopsy, all cases of high-grade
and some cases of low-grade disease were treated.
Additional ethical approval for the follow-up stage of the
study was obtained by the MREC involved with the original HART
study (Cuzick et al, 2003). Approval was given for passive outcome
follow-up of women attending routine screening, but a pathology
review of biopsies was not performed because of concerns about
the need to contact women if discrepancies were found.
Statistical methods
All eligible women from the baseline study were included (Cuzick
et al, 2003). Baseline test results were updated on the basis of
additional data available for the first year, which became available
after publication. These updated results were used to recalculate
sensitivity and specificity for CIN2 or worse (and CIN3 or worse)
within the first year for cytology and HPV. For follow-up results,
we included only women with at least one follow-up cytology result
at least 1 year after the initial baseline test. The main outcome of
interest was the presence of CIN2þ on histology after the initial
year. We also considered CIN3þ as a further outcome.
Histological events were backdated to the time of the preceding
cytology, and follow-up time at risk was taken from the date of the
initial baseline test until the date of the last cytology test recorded
for that individual. Outcomes were assessed by hazard ratios (HRs)
for time to event using the proportional hazards model. All
P-values are two sided. Statistical analyses were performed using
STATA (StataCorp. 2007. Stata Statistical Software: Release 10;
StataCorp LP, College Station, TX, USA).
RESULTS
Initial results for the baseline period have been published (Cuzick
et al, 2008), and have been updated to reflect additional histology
results within a year of the baseline visit (and additional cytology
within 1 year in cases in which only inadequate results were
previously available). Seventeen additional women with CIN2þ
were identified: one woman (CIN2) had no adequate cytology
within the first year but had an HPV-negative result; four women
(CIN3) had negative results for both cytology and HPV and the
remaining 12 women (six CIN2, six CIN3) had HPV-positive
results and a borderline or worse cytology. We found 107 women
with histologically confirmed CIN2 or worse within a year of this
visit. Table 1 shows the level of high-grade disease within a year of
the baseline test according to baseline HPV and cytology results.
Results were similar to those previously published, with a
sensitivity of HPV for CIN2þ of 92.5% (vs 97.1% previously)
and for cytology of 82.1% (vs 76.6% previously). For CIN3þ ,
sensitivity was 96.1% for HPV (97.1% previously) and 82.9% for
cytology (82.6% previously).
The trial profile (Figure 1) shows the number of women followed
up and the proportions with high-grade disease after the first year.
Follow-up time was defined as time between baseline test and last
subsequent smear test (any colposcopy or histology after the last
smear test has been included but the last follow-up date is still
considered as the date of cytology). A total of 8735 (84%) women
had at least one further smear recorded 1 year or more after entry,
with a median follow-up of 6 years (Birmingham: 1535 women, 6
years; Edinburgh: 1620 women, 5.6 years; London: 2194 women,
6.3 years; Manchester: 1075 women, 4.6 years; Mansfield: 2311
women, 6 years).
During follow-up, a further 42 cases of CIN2þ were found.
Table 2 shows the worst histology for each woman after the
baseline year. Four cases of CIN2þ were found during the follow-
up period among those who were HPV negative but cytology
positive. Three of these were CIN2, and they occurred in women
with borderline cytology between 19 and 52 months after entry.
One case of CIN3 occurred at 44 months, also after a borderline
entry smear. Sixteen cases of CIN2þ were found on follow-up in
women who were HPV positive but cytology negative (12 CIN2, 4
CIN3þ ) and 15 cases of CIN2þ were found in women who were
negative on both tests (seven CIN2, six CIN3þ ).
Of the 65 women with no adequate cytology in the first
year from the baseline test, 53 (81.5%) had a further smear more
than 1 year after baseline (50 HPV negative and 3 positive),
but among them, no high-grade disease was identified. Three
women had an ungraded CIN at some stage in their follow-up, of
whom two had an additional histological diagnosis within a period
of 2 months, which confirmed CIN3 (both HPV positive, one
cytology normal and one cytology moderate at baseline). The
remaining woman had no further follow-up recorded and this
result was taken to be CIN2 (cytology normal and HPV negative at
baseline).
HART: long-term follow-up of cytology and HPV testing
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Incidence of CIN2þ by baseline HPV and cytology results
A total of 27 (0.28%) women with a negative HPV test at baseline
(n¼ 9574) were identified as having CIN2þ at some stage. Eight
(30%) of them were identified in the baseline year and the
remaining 19 (70%) after this period. Including disease found at
baseline, the risk of developing CIN2þ at 1, 3, 5 and 8 years after a
negative HPV test result was 0.09, 0.12, 0.23 and 0.61%,
11 085 Women
10 358 Women from baseline paper
727 Women excluded
8735 Women with at least on follow-up
smear result (median follow-up 6.0 years)
8219 Baseline Cytology
Negative
194 Baseline Cytology Mild or
Worse
322 Baseline Cytology
Borderline or Inadequate**
7778 HC-II
Negative
441 HC-II
Positive
247 HC-II
Negative
75 HC-II
Positive
46 HC-II
Negative
148 HC-II
Positive
Med FU: 6.01
CIN2+ BL: 4
CIN2+ FU: 15
Med FU: 5.49
CIN2+ BL: 13
CIN2+ FU: 16*
Med FU: 5.37
CIN2+ BL: 2
CIN2+ FU: 4
Med FU: 5.60
CIN2+ BL: 7
CIN2+ FU: 6
Med FU: 5.79
CIN2+ BL: 2
CIN2+ FU: 0
Med FU: 5.74
CIN2+ BL: 71
CIN2+ FU: 2
Figure 1 The HART trial profile. *Includes 1 woman who had hgd at baseline and during follow-up. **53 women had no adequate Cytology within one
year of baseline.
Table 1 Baseline cytology and HPV vs worst histology in first year (reviewed histology)
Worst histology in first year
Inadequate
Normal/no.
of biopsy
HPV alone/
borderline CIN1 CIN2 CIN3 Adeno in situ Total
Cytology
Inadequate 2 59 3 0 0 1 0 65 (0.6)
Negative 155 9566 27 15 6 13 0 9782 (94.4)
Borderline 24 236 15 13 4 5 0 297 (2.9)
Mild 9 70 18 8 9 8 0 122 (1.2)
Moderate 1 16 1 2 9 13 0 42 (0.4)
Severe 0 3 2 3 2 30 3 43 (0.4)
Inv.Carc/Gland.Neo 0 3 0 0 0 1 3 7 (0.1)
HC-II (RLU ratio)
o0.3 (negative) 110 8278 21 18 5 1 0 8433 (81.4)
0.3–0.99 (negative) 17 1115 6 1 0 2 0 1141 (11)
1.0–1.99 (positive) 11 92 3 2 0 1 0 109 (1.1)
2.0–3.99 (positive) 8 79 3 2 1 3 0 96 (0.9)
4.0–9.99 (positive) 7 74 2 2 2 2 0 89 (0.9)
10+ (positive) 38 315 31 16 22 62 6 490 (4.7)
Total 191 9953 66 41 30 71 6 10358 (100)
(1.8) (96.1) (0.6) (0.4) (0.3) (0.7) (0.06)
Abbreviations: Inv.Carc/Gland.Neo¼ Possible invasive Carcinoma Glandular Neoplasia; RLU¼ relative light unit.
HART: long-term follow-up of cytology and HPV testing
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respectively. Figure 2 shows the rate of disease restricted to the
follow-up period only, being 0.04, 0.15 and 0.53% at 3, 5 and 8
years, respectively, after a negative HPV test result, and 2.14, 4.11
and 6.20%, respectively, after a positive HPV test result (HR 17.16
(95% confidence interval (CI) 9.3, 31.6), Po0.0001). There is a
clear increase in incidence of CIN2þ as the RLU ratio increases.
Compared with an RLU ratioo1, the HR (95% CI) for CIN2þ was
5.4 (1.6, 18.2) for 1–10 RLU and 25.2 (13.6, 47.9) for RLU X10
(test for trend, Po0.001).
In all, 49 (0.50%) women with a normal cytology result at
baseline (n¼ 9782) were identified as having CIN2þ at
some stage. Nineteen (39%) of them were identified in the baseline
year and the remaining 30 (61%) after this period. Including
any disease found at baseline, the risk of developing CIN2þ at 1,
3, 5 and 8 years after a normal cytology result was 0.21, 0.28,
0.48 and 1.04%, respectively. Figure 2 shows the cumulative
incidence of new high-grade disease restricted to follow-up
only, according to baseline cytology results. In those cytology
negative and cytology borderline or worse results, respectively, the
levels of CIN2þ were 0.07 vs 2.44% at 3 years, 0.28 vs 3.40% at 5
years and 0.84 vs 3.40% at 8 years (HR 8.74 (95% CI; 4.5, 17.1),
Po0.0001).
Of the 9247 women with both negative cytology and HC-II tests
at baseline, 19 (0.21%) had CIN2þ , including 4 identified within
the first year. Figure 3 shows rates of CIN2þ (including baseline
disease) according to baseline cytology and HPV result and shows
a condensed scale to allow a comparison of negative cases. Here,
we focus on individuals with discordant HPV/cytology results at
Table 2 Baseline cytology and HPV vs worst follow-up histology (local histology)
Worst follow-up histology after first year
Inadequate Normal/no. of biopsy HPV alone Borderline CIN1 CIN2 CIN3 Total
Cytology
Inadequate 16 37 0 0 0 0 0 53 (0.6)
Negative 230 7884 24 6 44 13 18 8219 (94.1)
Borderline 75 166 9 0 9 7 3 269 (3.1)
Mild 66 32 1 1 8 1 1 110 (1.3)
Moderate 33 4 2 0 2 0 0 41 (0.5)
Severe 34 2 0 0 2 0 0 38 (0.4)
Inv.Carc/Gland.Neo 4 1 0 0 0 0 0 5 (0.1)
HC-II (RLU ratio)
o0.3 (negative) 202 6842 22 5 29 12 6 7118 (81.5)
0.3–0.99 (negative) 32 910 2 0 8 0 1 953 (10.9)
1.0–1.99 (positive) 33 55 0 0 6 0 2 96 (1.1)
2.0–3.99 (positive) 15 58 2 0 1 0 0 76 (0.9)
4.0–9.99 (positive) 17 49 1 0 2 0 1 70 (0.8)
10+ (positive) 159 212 9 2 19 9 12 422 (4.8)
Total 458 8126 36 7 65 21 22 8735 (100)
(5.2) (93) (0.4) (0.08) (0.7) (0.2) (0.3)
Abbreviations: Inv.Carc/Gland.Neo¼ Possible invasive Carcinoma Glandular Neoplasia; RLU¼ relative light unit.
HPV RLU 1-10 pg ml–1 (Positive)
Cytology negative
0%
5%
10%
Analysis time (years)
0 1 2 3 4 5 6 7
Hazard ratio of negative vs positive HPV test:
17.2 (9.3, 31.6), P < 0.001       
Hazard ratio of negative vs borderline+ cytology:
8.7 (4.5, 17.1), P < 0.001
HPV RLU <1 pg ml–1 (Negative)
Cytology Borderline+
HPV RLU10 pg ml–1 (Positive)
Figure 2 Cumulative incidence of CIN2þ in the follow-up period according to baseline results.
All women
Cytology negative
HPV negative
Both negative
0%
1%
2%
Analysis time (years)
0 1 2 3 4 5 6 7
Figure 3 Cumulative incidence of CIN2þ according to baseline results.
HART: long-term follow-up of cytology and HPV testing
D Mesher et al
1408
British Journal of Cancer (2010) 102(9), 1405 – 1410 & 2010 Cancer Research UK
E
p
id
e
m
io
lo
g
y
baseline. For women who were HPV negative but had a borderline
or worse cytology result, 4 of 240 (1.67%) were found to have high-
grade disease in the follow-up period (rates at 3, 5 and 8 years were
0.43, 1.97 and 1.97%, respectively). For those with a negative
cytology but positive HPV test result, 15 of 428 (3.50%) CIN2þ
cases were identified and rates at 3, 5 and 8 years were 0.95, 3.60
and 6.20%, respectively.
DISCUSSION
These results confirm previous reports of a longer low-risk period
after a negative HPV test result than after a negative cytology
result(Cuzick et al, 2008; Dillner et al, 2008). It has long been
suspected that the higher initial detection with HPV testing should
lead to a longer low-risk period in those who are HPV negative. In
this multicentre study, we found that women with a negative HC-II
test result had a substantially lower rate of CIN2þ for at least 6
years when compared with those with a negative cytology result.
This adds more support for the proposition that the interval for
screening using HPV could be safely extended to at least 5 years.
Further support is provided by a recent Italian study in which
invasive cancer was also dramatically reduced in the follow-up
period after screening (nine after cytology testing vs none after
HPV testing) (Ronco et al, 2010). A strength of this study is that
screening and follow-up processes of these 8735 women were
performed in many centres across the United Kingdom as part of
the routine screening programme. Cytology and HPV testing was
performed on all women in the study, so that comparisons between
the two tests could be conducted in a manner that avoided
between-women variation. This is ideal for cross-sectional and
some longitudinal comparisons, but does not exactly reproduce
the results of a randomised trial in which women receive only
HPV test or cytology initially and thus would not have disease
identified by the other test detected so quickly. Such trials
need to be large to be informative, and given the number of
smaller trials of HPV testing already reported, it should be
large enough to demonstrate a reduction in a more distal end
point such as cancer incidence (Sasieni and Cuzick, 2002; Ronco
et al, 2010).
Women with HPV positive or cytology borderline results (or
both) were randomised to either immediate colposcopy or referral
to a further smear/HPV test in 12 months. The rate of CIN2þ in
the follow-up period was similar regardless of the randomisation
group. Therefore, results were unchanged regardless of whether
women are referred for immediate colposcopy or managed by
follow-up screening. Some overtreatment of lesions with CIN1 (or
less) based on the initial biopsy results will lead to lower disease
rates during follow-up. We recorded treatment of 17 of 65 (26.2%)
women with histologically confirmed CIN1 and 26 of 146 (17.8%)
women with a biopsy indicating less than CIN1.
In addition, the histology results in the follow-up phase were not
centrally reviewed because of concerns regarding contacting
women if there were discrepancies. Therefore, especially for
CIN2, which is known to have substantial inter-reader variability
and also uncertain progressive potential, it is possible that not all
of these were progressive lesions. An exit screen in which all
women receive both tests would help to minimise any ascertain-
ment bias. In addition, this study was performed in women aged
30–60 years so that it does not provide any evidence for the
relative benefits of cytology vs HPV testing in younger women,
wherein both tests have a higher positivity rate.
In summary, HPV testing offers improved protection from
CIN2þ after a negative test result compared with the protection
afforded from a normal cytology result. The risk of developing
CIN2þ after a negative HPV test result was extremely low at 5
years (0.23%) and was comparable with cytology at 3 years
(0.28%). These results provide additional support for using HPV as
the primary screening test, and indicate that the very high
sensitivity of HPV testing can not only lead to a more effective
screening programme but the resulting high negative predictive
value can safely allow longer screening intervals and result in a
more cost-effective programme as well.
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